Eli Lilly and Company (LLY) — closed signal from April 22, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 21, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$900.00 – $930.00Entry zone — fair-value band
$919.97Published — price the day we called it
$1,057.96Target — the price the thesis aimed for
$1,249.45Peak — highest point inside the window, not a realized return
$1,175.41Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 30 days.
Peak price
$1,249.45
peak on July 7, 2026 — not a realized returnPeak gain
+35.8%
peak, from the publication priceWindow close
$1,175.41
end-of-window price, context onlyDays to target
30
Window
April 22, 2026 – July 21, 2026
The thesis — published April 22, 2026
Predicted growth
+15%
over the measurement windowTarget price
$1,057.96
the price the thesis aimed forEntry zone
$900.00 – $930.00
the fair-value band we waited forPrice at publication
$919.97
published April 22, 2026Confidence
82%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly mixes steady demand with growth potential over the next quarter. Positive trial results and wider GLP-1 availability point to stronger sales for obesity and diabetes drugs, and the stock's recent pullback makes the timing more reasonable. The company still has momentum in its key drug areas, but recent headlines mean patience is helpful.
Primary drivers
- Obesity and diabetes drugs remain main growth engines
- Positive trial results support longer-lasting product demand
- Wider GLP-1 distribution increases potential customer reach
- Recent pullback makes the price setup more reasonable for recovery
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.